Payment overview · 2025
General Payments
$229.59
11 reported records · 7 companies
Healthcare provider profile · identity verified
Raymond Molano, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PORT ST LUCIE, FL · NPI 1417070376
Verified facts
What the public records show
CMS Open Payments records show Raymond Molano, MD received $229.59 in general payments during 2025 across 11 reported records.
GlaxoSmithKline, LLC. accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.95 | 38.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.98 | 18.3% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $27.83 | 12.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.96 | 8.7% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $18.87 | 8.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.63 | 8.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.37 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.59 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.95 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 79 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 521 | 156 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 126 |
| Losartan Potassium | Losartan Potassium | 359 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 356 | 108 |
| Celecoxib | Celecoxib | 328 | 150 |
| Lisinopril | Lisinopril | 302 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 108 |
| Metformin Hcl | Metformin Hcl | 253 | 88 |
| Alprazolam | Alprazolam | 246 | 55 |
| Omeprazole | Omeprazole | 203 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 58 |
| Methylprednisolone | Methylprednisolone | 157 | 124 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 56 |
| Trazodone Hcl | Trazodone Hcl | 147 | 56 |
| Tramadol Hcl | Tramadol Hcl | 134 | 37 |
| Meloxicam | Meloxicam | 133 | 63 |
| Gabapentin | Gabapentin | 132 | 48 |
| Simvastatin | Simvastatin | 126 | 42 |
| Furosemide | Furosemide | 125 | 46 |
| Azithromycin | Azithromycin | 124 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 37 |
| Montelukast Sodium | Montelukast Sodium | 115 | 37 |
| Pregabalin | Pregabalin | 96 | 35 |
| Temazepam | Temazepam | 90 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 30 |
| Ibuprofen | Ibuprofen | 81 | 33 |
| Eliquis | Apixaban | 79 | 28 |
| Atenolol | Atenolol | 75 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 16 |
| Allopurinol | Allopurinol | 70 | 17 |
| Carvedilol | Carvedilol | 67 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 17 |
| Glipizide | Glipizide | 56 | 24 |
| Donepezil Hcl | Donepezil Hcl | 55 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 13 |
| Ozempic | Semaglutide | 53 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 45 |
| Glimepiride | Glimepiride | 52 | 17 |
| Mometasone Furoate | Mometasone Furoate | 51 | 30 |
| Valsartan | Valsartan | 48 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 17 |
| Alendronate Sodium | Alendronate Sodium | 45 | 19 |
| Potassium Chloride | Potassium Chloride | 43 | 23 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Nabumetone | Nabumetone | 41 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Diazepam | Diazepam | 38 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 19 |
| Finasteride | Finasteride | 36 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 30 |
| Xarelto | Rivaroxaban | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 16 |
| Azelastine Hcl | Azelastine Hcl | 30 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 15 |
| Prednisone | Prednisone | 30 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 19 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 17 |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Minoxidil | Minoxidil | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | 11 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | 13 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 16 |
| Glyburide | Glyburide | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Acetic Acid | Acetic Acid | 14 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.59 · 11 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, ELIQUIS, JARDIANCE, NURTEC ODT, OTEZLA, REPATHA, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, Tymlos | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error